Please assess the completion status of the following clinical trial:

Trial Title: Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Informed Consent.~2. Men and women ≥ 50 years of age.~3. Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye.~4. Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) of: letter score of 73 to 25 (20/40 to 20/320) in the study eye at 4 meters.~5. Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.~6. Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member. See Appendix J.4) understand and willing to sign the informed consent form.~Key~Exclusion Criteria:~1. Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins.~2. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins.~3. Any prior treatment with anti-VEGF agents in the study eye.~4. Total lesion size \> 12 disc areas (30.5 mm\^2, including blood, scars and neovascularization) as assessed by FA in the study eye.~5. Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible CNV.)~6. Scar or fibrosis, making up \> 50% of total lesion in the study eye.~7. Scar, fibrosis, or atrophy involving the center of the fovea.~8. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.~9. History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.~10. Presence of other causes of CNV in the study eye.~11. History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina,other than AMD, in either eye.~12. Prior vitrectomy in the study eye.~13. History of retinal detachment or treatment or surgery for retinal detachment in the study eye.~14. Any history of macular hole of stage 2 and above in the study eye.~15. Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as its unlikely to interfere with the injection.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ranibizumab 0.5mg Q4 (Type: ACTIVE_COMPARATOR): None
- aflibercept injection 2.0mg Q4 (Type: EXPERIMENTAL): None
- aflibercept injection 0.5mg Q4 (Type: EXPERIMENTAL): None
- aflibercept injection 2.0mg Q8 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete